Drug intelligence / Profile preview

99mTc-1-thio-D-glucose

Development stage: Phase 2
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

99mTc-1-thio-D-glucose is a radiopharmaceutical agent that binds to glucose transport proteins (GLUT receptors). It functions similarly to [18F]FDG but uses technetium-99m as the radioisotope, making it suitable for SPECT imaging rather than PET. The compound has shown high labeling efficiency (>97%) and demonstrates higher stability at acidic pH compared to neutral and basic pH. It is being investigated primarily for tumor imaging, particularly in lymphoma patients.

Other names: 99mTc-TG99mTc-1-TG

Targets

SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)

Beyond the preview

Go deeper on 99mTc-1-thio-D-glucose.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 99mTc-1-thio-D-glucose.

Explore the full profile